Tumor markers AFP, CA 125, and CA 19-9 in the long-term follow-up of sacrococcygeal teratomas in infancy and childhood

Tumor Biology

Volumn 31, Issue 4, 2010, Pages 261-265

  Pauniaho, Satu Liisa ^a   Tatti, Olga ^b   Lahdenne, Pekka ^b   Lindahl, Harry ^b   Pakarinen, Mikko ^b   Rintala, Risto ^b   Heikinheimo, Markku ^b  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

AFP; CA 125; CA 19 9; Tumor markers

Indexed keywords

ALPHA FETOPROTEIN; CA 125 ANTIGEN; CA 19-9 ANTIGEN; TUMOR MARKER;

ADENOCARCINOMA; ADOLESCENT; ARTICLE; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HUMAN; MALE; NEPHROBLASTOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REFERENCE VALUE; REOPERATION; SACROCOCCYX TERATOMA; TUMOR RECURRENCE; ULTRASOUND; YOLK SAC TUMOR; BACK; BLOOD; ENZYME IMMUNOASSAY; METABOLISM; NEWBORN; PATHOLOGY; PROGNOSIS; SPINAL CORD TUMOR; SURVIVAL RATE; TERATOMA; TIME;

ALPHA-FETOPROTEINS; CA-125 ANTIGEN; CA-19-9 ANTIGEN; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; INFANT, NEWBORN; MALE; PROGNOSIS; SACROCOCCYGEAL REGION; SPINAL NEOPLASMS; SURVIVAL RATE; TERATOMA; TIME FACTORS;

EID: 77954639264     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-010-0026-8     Document Type: Article

References (18)

1. Tapper D, Lack EE. Teratomas in infancy and childhood. A 54- year experience at the Children's Hospital Medical Center. Ann Surg. 1983;198:398-410.
2. Woolley MM. Teratomas. In: Ashcraft KW, Holder TM, editors. Pediatric surgery. 2nd ed. Philadelphia: Saunders; 1993. p. 847-62.
3. Rescorla FJ, Sawin RS, Coran AG, Dillon PW, RGl A. Long-term outcome for infants and children with sacrococcygeal teratoma: a report from the Children's Cancer Group. J Pediatr Surg. 1998;33:171-6.
4. Billmire DF. Malignant germ cell tumors in childhood. Semin Pediatr Surg. 2006;15:30-6.
5. Lahdenne P, Heikinheimo M. Clinical use of tumor markers in childhood malignancies. Ann Med. 2002;34:316-23.
6. Daoud E, Bodor G. CA-125 concentrations in malignant and nonmalignant disease. Clin Chem. 1991;37:1968-74.
7. Bast Jr RC, Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GB. CA 125: the past and the future. Int J Biol Markers. 1998;13:179-87.
8. Haglund C, Roberts PJ, Jalanko H, Kuusela P. Tumour markers CA 19-9 and CA 50 in digestive tract malignancies. Scand J Gastroenterol. 1992;27:169-74.
9. Lahdenne P, Pitkänen S, Rajantie J, Kuusela P, Siimes MA, Lanning M, et al. Tumor markers CA 125 and CA 19-9 in cord blood and during infancy: developmental changes and use in pediatric germ cell tumors. Pediatr Res. 1995;38:797-801.
10. Lahdenne P, Kuusela P, Siimes MA, Lanning M, Heikinheimo M. Biphasic reduction and concanavalin A binding properties of serum alpha-fetoprotein in preterm and term infants. J Pediatr. 1991;118:272-6.
11. Aula P, Rapola J, Karjalainen O, Lindgren J, Hartikainen AL, Ml S. Prenatal diagnosis of congenital nephrosis in 23 high-risk families. Am J Dis Child. 1978;132:984-7.
12. Wald NJ, Cuckle HS, Boreham J, Stirrat GM, Turnbull AC. Maternal serum alpha-fetoprotein and low birth weight in relation to gestational age. Br J Obstet Gynaecol. 1982;89:216-7.
13. Huddart SN, Mann JR, Robinson K, Raafat F, Imeson J, Gornall P, et al. Children's Cancer Study Group. Sacrococcygeal teratomas: the UK Children's Cancer Study Group's experience. I Neonatal Pediatr Surg Int. 2003;19:47-51.
14. Gabra HO, Jesudason EC, McDowell HP, Pizer BL, Losty PD. Sacrococcygeal teratoma-a 25-year experience in a UK regional center. J Pediatr Surg. 2006;41:1513-6.
15. Draper H, Chitayat D, Ein SH, Langer JC. Long-term functional results following resection of neonatal sacrococcygeal teratoma. Pediatr Surg Int. 2009;25:243-6.
16. Bilik R, Shandling B, Pope M, Thorner P, Weitzman S, Ein SH. Malignant benign neonatal sacrococcygeal teratoma. J Pediatr Surg. 1993;28:1158-60.
17. Salonen J, Leminen A, Stenman UH, Butzow R, Heikinheimo M, Heikinheimo O. Tissue AP-2gamma and Oct-3/4, and serum CA 125 as diagnostic and prognostic markers of malignant ovarian germ cell tumors. Tumour Biol. 2008;29:50-6.
18. Petäjä J, Pitkänen S, Vettenranta K, Fasth A, Heikinheimo M. Serum tumor marker CA 125 is an early and sensitive indicator of veno-occlusive disease in children undergoing bone marrow transplantation. Clin Cancer Res. 2000;6:531-5.